ClinicalTrials.gg
CompletedNCT07097831Updated Jan 9, 2026

A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects

A Phase 1 interventional study of HRS-1301 Tablets and Rosuvastatin Calcium Tablets in Hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
13th of 14
16 · median 78
Started
2025
with 4 others
Phase 1
8 of 14
none open now
Registered
8th of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 13th largest by enrollment, is one of 5 that started in 2025, is one of 8 in phase 1, and was the 8th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study was designed to evaluate the pharmacokinetic effects of rosuvastatin calcium tablets after oral administration of HRS-1301 in healthy subjects.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, aged 18-55 years (inclusive).
  2. At screening, 18.0 ≤ ≤ 30 kg/m2 (inclusive), and body weight ≥ 50.0 kg and \<90.0 kg for males and ≥ 45.0 kg and \< 90.0 kg for females.
  3. Physical examination, vital signs, , chest X-ray /CT, abdominal ultrasound, laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function, thyroid function) were normal or abnormal but of no clinical significance.
  4. The female subjects were not pregnant or lactating, and the results of pregnancy tests before the test were negative. Those who did not have unprotected sex within two weeks before screening; Female subjects of and men whose partners were women of childbearing age agreed to comply with relevant requirements and had no sperm/egg donation plans.
  5. Participants were able to communicate well with the investigators, understand and comply with the requirements of the study, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Previous medical history or current clinical diagnosis of cardiac, respiratory, endocrine, metabolic, cutaneous, infectious, malignant tumor, hematologic, neurological or psychiatric disorders, metabolic/functional disorders or other diseases.
  2. Gastrointestinal, hepatic, or renal disease, as judged by the investigator, or other conditions known to affect the absorption, distribution, metabolism, and excretion of the drug or to impair adherence.
  3. Patients with major trauma or surgery within 3 months before screening or planning to undergo surgery during the trial.
  4. Patients with specific allergic history (asthma, urticaria, eczema, etc.), or allergic constitution (such as allergic to any drug, food), or known allergic to any ingredient in the study drug.
  5. Participants who had used any drugs (including prescription drugs, over-the-counter drugs, herbal medicines, dietary supplements, etc., except regular vitamins and occasional acetaminophen) within 2 weeks before screening, or within 5 half-life periods of the drugs (whichever was longer).
  6. Enrolled in a clinical trial of any drug or medical device within 3 months before screening or within 5 half-lives of the drug before screening, whichever is longer.
  7. Individuals who have donated ≥ 400 mL blood within 4 weeks before screening, have severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 8 weeks before screening.
  8. Persons who are scheduled to receive live (attenuated) vaccine within 4 weeks before screening or during the course of the trial.
  9. virus surface antigen, virus IgG antibody, anti-treponema pallidum antibody, antibody and antigen p24 positive during the screening period.
  10. Those with positive alcohol breath test and/or drug abuse screening test at baseline.
  11. A history of drug or substance abuse.
  12. Potential difficulty in blood collection, with a history of syncope.
  13. Investigators, research assistants, pharmacists, research coordinators, or others directly involved in the implementation of the protocol.
  14. Any factors considered by the investigator to be unsuitable for participation in the trial.
  15. Subjects voluntarily withdraw from the trial due to their own reasons.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Drug: HRS-1301 Tablets · Drug: Rosuvastatin Calcium Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve from time 0 to time t (AUC0-t)

    Time frame: 0 to anticipated 15 days.

  2. Area under the curve from time 0 to time infinity (AUC0-∞)

    Time frame: 0 to anticipated 15 days.

  3. Maximum concentration (Cmax)

    Time frame: 0 to anticipated 15 days.

Secondary outcomes

  1. Time to reach maximum concentration (Tmax)

    Time frame: 0 to anticipated 15 days.

  2. Half-life (t1/2)

    Time frame: 0 to anticipated 15 days.

  3. Apparent clearance (CL/F)

    Time frame: 0 to anticipated 15 days.

  4. Adverse events (AEs)

    Time frame: Baseline up to 19 days.

07

Study locations

1 site
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Nov 2025, 0 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 0 months is below that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Oct 9, 2025
Primary completionActual
Nov 7, 2025
CompletionActual
Nov 7, 2025
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07097831
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Oct 9, 2025
Primary completion
Nov 7, 2025
Completion
Nov 7, 2025
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1301

Start the discussion